Synthetic GnRH (gonadotropin-releasing hormone) decapeptide
A synthetic copy of the natural hypothalamic hormone that signals the pituitary to release LH and FSH.
| Class / type | Synthetic GnRH (gonadotropin-releasing hormone) decapeptide |
|---|---|
| Category | Hormones & Reproductive |
| Status (Jul 2026) | Compounded (Rx) |
Gonadorelin binds pituitary GnRH receptors; pulsatile dosing stimulates LH and FSH release, whereas continuous exposure downregulates receptors and suppresses gonadotropins.
Historically for evaluating pituitary gonadotropin function and inducing ovulation; now commonly compounded and used off-label in men's health/TRT to maintain testicular function and endogenous testosterone.
Stimulates the body's own LH/FSH release; short half-life allows physiologic pulsatile dosing; used as an HCG alternative in TRT protocols.
Very short half-life requires frequent dosing; injection-site reactions, headache, nausea, flushing; efficacy for testicular maintenance is less established than HCG; compounded products lack the oversight of approved drugs.
TRT users often prefer it as a lighter alternative to HCG, though some report inconsistent results and dislike frequent injections.
Former FDA approval - the branded products (Factrel, Lutrepulse) were discontinued and no FDA-approved gonadorelin is currently marketed in the US; it is now available only through compounding pharmacies.